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Abstract
Background: Crohn's disease (CD) and multiple sclerosis (MS) share common pathogenic processes.
Interferon (IFN) beta-1a is effective and generally well tolerated in patients with MS and has been shown
to down-regulate the expression of interleukin-12, a cytokine that is thought to be involved in mucosal
degeneration in CD. IFN beta-1a therefore offers promise as a treatment for CD.
Methods: In this multicentre, double-blind, placebo-controlled, phase II, dose-finding study, patients with
steroid-induced clinical remissions of CD were randomized 1:1:1:1 to subcutaneous IFN beta-1a: 66 mcg
three times weekly (tiw), 44 mcg tiw, 44 mcg twice weekly (biw), or matching placebo tiw with steroid
tapering. The primary endpoint was the proportion of patients relapse-free at Week 26. Safety was also
assessed.
Results: This study was terminated early following a planned interim analysis at 26 weeks. Of the planned
192 patients, 67 were randomized to treatment: placebo (n = 16), or IFN beta-1a 44 mcg biw (n = 17), 44
mcg tiw (n = 16) or 66 mcg tiw (n = 18). In total, 20/67 patients (29.9%) completed 26 weeks and 7 patients
(10.4%) completed 52 weeks. The proportion of patients who remained relapse-free at Week 26 did not
differ significantly between the placebo group (5/16, 31%) and the IFN beta-1a 44 mcg biw (6/17, 35%; p =
0.497), 44 mcg tiw (7/16, 44%; p = 0.280) or 66 mcg tiw (2/18, 11%; p = 0.333) groups. There was little
difference between treatment groups in secondary efficacy endpoints. IFN beta-1a was generally well
tolerated at all doses. Adverse events (AEs) were generally mild or moderate in IFN beta-1a-treated
patients, with the most common AEs (influenza-like symptoms, headache, injection-site reactions) being
similar to those reported with IFN beta-1a in MS.
Conclusion: There was no difference in efficacy between patients with CD receiving IFN beta-1a or
placebo. However, these results should be considered in the context of the low patient numbers and high
dropout rate. Overall, IFN beta-1a was generally well tolerated, with a safety profile that was consistent
with previous experience in MS.
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Background
Crohn's disease (CD) is an inflammatory, autoimmune
disease of the bowel that causes non-specific symptoms
including abdominal pain, diarrhoea, anorexia and
fatigue. The aetiology of CD is unknown [1] with environ-
mental, immune, psychological and genetic factors
believed to be involved [2,3]. CD is thought to arise pri-
marily due to inappropriate chronic T-lymphocyte activa-
tion, with tissue damage induced by secondary
macrophage activation [4,5]. The prospect that CD is a
form of T-helper type 1 (Th1) cell-dominant autoimmune
disease is gaining acceptance, with support from the cur-
rent use of immunosuppressants [4,5].
There is currently no cure for CD, although various agents
are used to induce and maintain remission and improve
quality of life [6-8]. These include 5-aminosalicylic acid
(5-ASA); antibiotics, such as ciprofloxacin and metronida-
zole; systemic or topical corticosteroids; and immunosup-
pressants, such as methotrexate and thiopurines
(azathioprine, 6-mercaptopurine). There are, however,
limitations associated with each of these conventional
therapies, such as poor or unproven efficacy (5-ASA, anti-
biotics, azathioprine), potentially serious side-effects
(corticosteroids, methotrexate), or a slow onset of action
(thiopurines) [9]. More recently, infliximab and adalimu-
mab (anti-tumour necrosis factor alpha) have been
approved for use in patients with moderate-to-severe CD,
natalizumab (anti-alpha-4 integrin) has been rejected in
Europe for the treatment of CD (regulatory evaluation is
ongoing in the USA) and a number of other biological
therapies are in development for CD [10].
CD is an autoimmune condition characterized by a
marked infiltration and accumulation of activated Th1-
type CD4+ T cells and macrophages in inflamed intestinal
mucosa, suggesting that the Th1 cell plays an important
role in the pathogenesis of tissue damage in CD [4,5].
Studies indicate that the cytokine interleukin (IL)-12, the
major Th1-inducing factor, contributes to the local
inflammatory response in CD [11]. Indeed, studies con-
sistently demonstrate that IL-12 levels are elevated in CD
mucosa, and that boosting lamina propria Th1-cell
responses with IL-12 produces severe mucosal degenera-
tion [12-15]. Murine models have also shown that neu-
tralization of IL-12 leads to a rapid and complete recovery
of experimental colitis resembling CD [16]. Studies of
anti-IL-12 antibodies in CD have reported beneficial
effects [10].
Interferon (IFN) beta-1a, 44 mcg administered subcutane-
ously (sc) three times weekly (tiw) (Rebif®, Merck Serono
S.A. – Geneva, Switzerland), is an approved treatment for
patients with relapsing forms of multiple sclerosis (MS).
Among other pathogenic targets, IFN beta has been
shown to down-modulate T-cell activation by altering the
expression of proteins involved in antigen presentation,
and studies indicate that it also promotes the differentia-
tion of activated T cells away from a Th1 response (pro-
inflammatory) and towards a T-helper-type 2 (Th2)
response (anti-inflammatory) [17]. Accordingly, IFN beta
down-regulates the expression of IL-12 and promotes the
expression of anti-inflammatory cytokines [17].
Given these mechanisms of action, and the consistent effi-
cacy and tolerability of IFN beta-1a in patients with MS
[18], it was of interest to discover whether IFN beta-1a
could offer effective treatment for CD, with fewer side-
effects and toxicity issues than existing treatments. A dose-
finding study was conducted to investigate the efficacy
and tolerability of IFN beta-1a in patients with CD. The
standard dose used for the treatment of MS (44 mcg tiw)
was compared with two doses lying on either side of the
recommended weekly dosage regimen: one the same dose
but less frequent (44 mcg twice weekly [biw]), and the
other a higher dose with the same frequency (66 mcg tiw).
Methods
This was a 52-week, multicentre (40 investigators in seven
countries from North America and Europe), double-
blind, placebo-controlled, phase II, dose-finding study
(protocol 22916) of IFN beta-1a sc for the maintenance of
remission in adult patients with CD. Written informed
consent was obtained from each study participant before
the initiation of the study.
Ethical approval
The study was approved by the local ethics committees
(ECs) or institutional review boards (IRBs), and con-
ducted between December 2001 and September 2003
according to the principles of good clinical practice and
with the ethical principles of the Declaration of Helsinki
(2000) [19,20]. A complete listing of the ethics commit-
tees that granted approval for the study is listed below:
Belgium
Commissie Voor Medische Ethiek/Klinisch Onderzoek,
Leuven
Germany
Ethikkommission der Landesärztekammer Westfalen-
Lippe, Münster; Ethikkommission der Medizinischen
Fakultat der CAU, Kiel; Ethikkommission der Landesärz-
tekammer Schleswig-Holstein, Bad Segeberg
Italy
Comitato Etico Indipendente Locale, Azienda Ospe-
daliera "Ospedale Policlinico Consorziale" di Bari, Bari
Norway
Regional Etikk Komite Sor, OsloBMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
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Serbia
Ethics Committee and Committee for Drugs, Military
Medical Academy, Belgrade; Clinical Centre Serbia Ethical
Committee, Belgrade; Klinicki Centar Zemun Eticki
Komitet, Beograd-Zemun
Sweden
Research Ethical Committee, Department of Medicine-
Odontology, Umeå University, Umeå
United Kingdom
Huntingdon Local Research Ethics Committee, Papworth
Hospital, Cambridge; Cambridge Local Research Ethics
Committee, Addenbrooke's NHS Trust, Cambridge;
Rotherham Health Authority Local Research Ethics Com-
mittee, Rotherham.
Study objectives
The primary objective was to determine the optimal dose
of IFN beta-1a, based on safety and efficacy, for maintain-
ing remission of CD in patients in whom remission had
been achieved using steroids in the 4 weeks prior to study
entry. Secondary objectives included determining the
effect of IFN beta-1a on the time to relapse, patients' qual-
ity of life (using the Inflammatory Bowel Disease Ques-
tionnaire [IBDQ]), Crohn's Disease Activity Index (CDAI)
score, biological markers of inflammation, fistulas and
antibodies to IFN beta-1a.
Patients
IFN beta-naïve patients aged 18 years or older were
included if they had an established diagnosis of CD by
standard criteria (i.e. endoscopy, histology, barium con-
trast radiograph of gastrointestinal tract, or other recog-
nized criteria) and had gone into remission, defined as a
decrease in the CDAI to ≤150 points, using corticosteroids
within 4 weeks prior to study day 1 (SD1). On SD1,
patients were to be receiving ≥20 mg/day and ≤40 mg/day
of prednisone or its equivalent, or 6–9 mg/day of budeso-
nide, and to be able to comply with and tolerate the ster-
oid-tapering schedule. Steroid tapering was performed
over a maximum of 11 weeks (depending on dose at study
entry), as follows. Prednisone (or prednisone equivalent)
dosage was reduced on a weekly basis in increments of 5
mg/day down to a dosage of 10 mg/day, and thereafter by
weekly increments of 2.5 mg/day, until complete with-
drawal. Budesonide dosage was reduced by 3.0 mg/day at
3-weekly intervals from 9.0 mg/day to 3.0 mg/day, fol-
lowed by complete withdrawal after 4 weeks of the 3.0
mg/day dose. Patients were not to have been taking anti-
inflammatory agents, immunosuppressants, immu-
nomodulators and anti-cytokines for >2 weeks preceding
the day of study screening, and they were not to have been
receiving any other therapy for the maintenance of remis-
sion in CD. Patients were required to have adequate bone
marrow reserve (defined by white blood cell count ≥3.5 ×
109/L, neutrophils ≥1.5 × 109/L, thrombocytes ≥100 ×
109/L and haemoglobin ≥8.5 g/dL), adequate liver func-
tion (defined by total bilirubin, aspartate aminotrans-
ferase, alanine aminotransferase or alkaline phosphatase
levels <2 times the upper limit of normal) and adequate
renal function (defined by serum creatinine level <2.0
mg/dL). Female patients had to be post-menopausal, sur-
gically sterilized or to have agreed to use appropriate con-
traception for the duration of the study, and to have been
neither pregnant nor breast-feeding.
Patients were excluded if they required maintenance treat-
ment for the management of CD or had participated in
any other investigational study or received an experimen-
tal therapeutic procedure considered to interfere with the
study within 3 months of SD1. Patients could not have
had a stoma, symptoms of intestinal stenosis regarded
mainly as non-inflammatory, active infection, or a history
of cancer or systemic disease that could have interfered
with patient safety, compliance or evaluation of CD.
Table 1: Summary of efficacy and safety assessments carried out throughout the study
Treatment period (weeks) Post-treatment period (weeks)
S D 1261 01 41 82 22 63 44 25 24
E f f i c a c y  a n d  s a f e t y  a s s e s s m e n t s * X X XXXXXXXXX
IBDQ assessment X X X
C D A I  a s s e s s m e n t X X X XXXXXXXX
C R P X X X XXXXXX
E S R X X X XXXXXX
Antibodies to IFN beta-1a X X X
Thyroid function X X X
Urinalysis X X X X
Pregnancy testing X X X X X
CDAI: Crohn's disease activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IBDQ: inflammatory bowel disease 
questionnaire; IFN, interferon; SD1, study day 1
*Safety data were obtained by monitoring adverse events/serious adverse events, concomitant medications, physical examinations, vital signs and 
routine analysis of blood (haematology and chemistry)BMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
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Patients were also excluded if they needed emergency sur-
gery (for uncontrollable haemorrhage, persistent non-
inflammatory intestinal obstruction or perforation), had
scheduled elective surgery (during the study period) or
had surgery in the 4 weeks preceding SD1, or if they had
an unstable psychiatric disorder, severe depressive disor-
der and/or suicidal ideation, epilepsy with a history of sei-
zures not adequately controlled by treatment, or allergies
to paracetamol, human serum albumin or mannitol.
Two main populations were analysed in this study: a
modified intention-to-treat (ITT) population for efficacy
parameters and an 'all treated patients' population for
safety parameters. The modified ITT population com-
prised all randomized patients who received ≥1 injection
of the study medication and had data from ≥1 post-SD1
visit. A modified ITT population was used because 1
patient in the placebo group had received IFN beta-1a 66
mcg tiw in error throughout the study. Data for this
patient are presented according to the treatment received
and not the randomized treatment group. The 'all treated
patients' population included patients who were rand-
omized and who received ≥1 injection of study medica-
tion.
Treatment
Patients underwent randomization (1:1:1:1) to one of
four groups: IFN beta-1a 66 mcg tiw, IFN beta-1a 44 mcg
tiw, IFN beta-1a 44 mcg biw or matching placebo tiw
(same excipients but no IFN beta-1a). Treatment was to be
self-administered by sc injection for a total of 52 weeks.
Randomization took place within 24 hours prior to the
first dose of study medication, according to a computer-
generated randomization list stratified by geographical
region, which was allocated through a centralized tele-
phone randomization system.
The efficacy and safety assessments carried out at each visit
from SD1 to 4 weeks following the last injection are sum-
marized in Table 1.
Efficacy measures
The primary efficacy endpoint was the proportion of
patients who maintained remission (relapse-free) and did
not receive any additional treatment for the management
of CD by Week 26. Relapse was defined by an increase in
the CDAI to a total score of ≥200 points at any time, and
by an increase in the CDAI of >70 points from SD1 meas-
ured at two consecutive visits.
Secondary efficacy endpoints assessed the effect of treat-
ment with IFN beta-1a on the following: the proportion
of patients who maintained remission (relapse-free) and
did not receive any additional treatment for the manage-
ment of CD by Week 52; time to relapse; and change from
SD1 to end of treatment in the quality-of-life (IBDQ)
score, CDAI score, biological markers of inflammation
(C-reactive protein and erythrocyte sedimentation rate),
number of fistulas (including new fistulas and closure of
existing ones) and antibodies to IFN beta-1a. Blood sam-
ples taken at SD1, Week 26 and Week 52 were tested for
the presence of binding antibodies (BAbs) and, if found
Patient disposition Figure 1
Patient disposition. biw: twice weekly. IFN: interferon. tiw: three times weekly.BMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
Page 5 of 10
(page number not for citation purposes)
positive (defined as a titre ≥20 neutralizing units [NU]/
mL), were assessed for neutralizing activity. Patients with
a neutralizing antibody (NAb) titre of ≥20 NU/mL were
considered to have a positive result for NAbs.
Safety measures
Safety endpoints included the incidence of adverse events
(AEs) and serious AEs, and changes in clinical and labora-
tory parameters from SD1.
Interim analysis of the secondary endpoints was added as an
amendment to the protocol in January 2003 because the
study had been recruiting slowly and patient dropout rates
had been high (Figure 1). This analysis was to allow for early
discontinuation of the study in the case of lack of efficacy.
Statistical analysis
All statistical analyses were performed using SAS® Version
6.12 software (SAS Institute Inc.; Cary, NC, USA). A sam-
ple size of 43 patients per treatment group was needed to
provide 70% power to detect a significant difference in the
primary endpoint. This calculation was performed using a
two-sided chi-squared test and assumed a type I error rate
of 10%. Calculations were based on the assumption that
the proportion of patients who maintained remission and
did not receive additional treatment for CD at 26 weeks in
the placebo group would be 25% and would be at least
50% in an effective interferon beta-1a group.
All data were summarized using descriptive statistics. The
difference between groups was assessed using analysis of
variance on raw or ranked data (demographics and CDAI
at SD1), a logistic regression model (primary and second-
ary efficacy endpoints) or a Cox model (time to relapse)
with effects for treatment and region. All tests were per-
formed at a 10% significance level. Because of the small
number of patients in each treatment group, the differ-
ences between groups were not analysed for the change
from baseline (SD1) in a number of the secondary end-
points (IBDQ score, CDAI score, biological markers of
inflammation, antibodies to IFN beta-1a and number of
fistulas). Continuous (quantitative) variables were tabu-
lated using the following summary statistics: number of
values, mean, standard deviation (SD), and median and
range (minimum to maximum). Discrete (qualitative/cat-
egorical) variables were tabulated using frequencies and
percentages. An interim analysis of study data was per-
formed at Week 26 and used to assess study futility. This
used the method of O'Brien-Fleming to adjust for the
overall type I error level when analysing secondary effi-
cacy variables.
Results
Patients
This study was terminated early due to lack of efficacy, fol-
lowing an interim analysis of the 26-week data. In all, 67
of the planned 192 patients underwent randomization.
Of these, 16 received placebo, 17 received IFN beta-1a 44
mcg biw, 16 received IFN beta-1a 44 mcg tiw and 18
received IFN beta-1a 66 mcg tiw (Figure 1). Table 2 sum-
marizes the key baseline (SD1) demographic information
and clinical characteristics of the patients recruited. More
Table 2: Baseline demographic data and clinical characteristics*
Characteristics Placebo (n = 16) IFN beta-1a 44 mcg 
biw (n = 17)
IFN beta-1a 44 mcg 
tiw (n = 16)
IFN beta-1a 66 mcg 
tiw (n = 18)
Total (n = 67)
Mean (SD) age (years) 37.6 (13.6) 42.1 (14.8) 39.4 (12.9) 35.1 (11.9) 38.5 (13.3)
Mean (SD) BMI (kg/m2) 23.5 (7.8) 24.2 (6.4) 24.4 (4.7) 24.3 (5.8) 24.1 (6.1)
Sex
Male 8 (50) 6 (35.3) 7 (43.8) 7 (38.9) 28 (41.8)
Female 8 (50) 11 (64.7) 9 (56.3) 11 (61.1) 39 (58.2)
Race
White 15 (93.8) 17 (100) 16 (100) 17 (94.4) 65 (97)
Hispanic 1 (6.3) 1 (5.6) 2 (3)
Diagnosis confirmed by: 14 (87.5) 15 (88.2) 12 (75) 15 (83.3) 56 (83.6)
Endoscopy 11 (68.8) 11 (64.7) 12 (75) 10 (55.6) 44 (65.7)
Histology 6 (37.5) 8 (47.1) 9 (56.3) 10 (55.6) 33 (49.3)
Barium contrast 
radiography
4 (25) 4 (23.5) 6 (37.5) 4 (22.2) 18 (26.9)
Other
Surgery
Yes 5 (31.3) 3 (17.6) 2 (12.5) 4 (22.2) 14 (20.9)
No 11 (68.8) 14 (82.4) 14 (87.5) 14 (77.8) 53 (79.1)
Mean CDAI total 
score
100.8 92.1 80.4 79.2 87.9
biw: twice weekly; BMI: body mass index; CDAI: Crohn's Disease Activity Index; IFN: interferon; SD, standard deviation; tiw: three times weekly
*Data are presented as number (%) unless indicated otherwise; percentages may not sum to 100 due to roundingBMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
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than 93% of patients in each treatment group (97% over-
all) were white, with the remainder Hispanic. Patient
demographic and clinical characteristics were well bal-
anced, with no statistically significant differences between
the four treatment groups. Overall, the diagnosis of CD
was confirmed most frequently by endoscopy (56/67,
84%) and histology (44/67, 66%). In all, 51% of patients
(34/67) had CD on the left side of the colon, 51% (34/67)
had CD on the right side of the colon, and 69% (46/67
patients) had CD in the ileum. The majority of patients
had not undergone surgery for their CD, although approx-
imately half had undergone some other procedure (52%;
35/67 patients). The mean ± SD CDAI score at baseline
was highest for the placebo group (100.8 ± 47.1) and low-
est for the IFN beta-1a 66 mcg tiw group (79.2 ± 30.0).
There was no significant difference in baseline CDAI score
among the treatment groups. Additional baseline charac-
teristics summarized included those assessed for second-
ary endpoints, past and current medical conditions,
smoking history, electrocardiographic findings, individ-
ual variables of the CDAI and duration of CD. There were
no significant differences among the treatment groups for
any of these additional baseline characteristics.
A total of 20 patients (29.9%) completed 26 weeks and 7
patients (10.4%) completed 52 weeks of the study. Of the
60 patients who discontinued prior to 52 weeks, the rea-
sons for discontinuation were: treatment failure (40%,
27/67 patients); AEs (15%, 10/67 patients); major proto-
col violation (3.0%, 2/67 patients); non-compliance
(3.0%, 2/67 patients); lost to follow up (1.5%, 1/67
patients); or 'other reasons' (27%, 18/67 patients). One
patient who had undergone randomization to the placebo
group received IFN beta-1a 66 mcg tiw in error through-
out the study. This patient is presented in all tables and
figures according to the treatment received and not the
randomized treatment group. Nine patients had inclusion
or exclusion criteria deviations at study entry; none of
these were considered major protocol deviations. Five of
these patients were granted exceptions and allowed to
continue in the study. The remaining 4 patients (2 in the
placebo group, 1 in the IFN beta-1a 44 mcg tiw group and
1 in the IFN beta-1a 66 mcg tiw group) had not gone into
remission using corticosteroids within the 4 weeks prior
to SD1. These deviations were not discovered until after
the patients had started treatment and, although excep-
tions were not granted, these patients continued to partic-
ipate in the study.
Efficacy
With respect to the primary outcome, there were no signif-
icant differences in the proportion of patients who
remained relapse-free without additional treatment at
Week 26 between the placebo group (5/16, 31%) and the
IFN beta-1a 44 mcg biw (6/17, 35%; p = 0.497), 44 mcg
Proportion of patients who maintained remission (relapse-free) at Week 26 or Week 52 and did not receive additional treat- ment for Crohn's disease Figure 2
Proportion of patients who maintained remission (relapse-free) at Week 26 or Week 52 and did not receive 
additional treatment for Crohn's disease. biw: twice weekly; IFN: interferon; tiw: three times weekly. *p < 0.05 in favour 
of placebo over IFN beta-1a 66 mcg tiw at Week 52.BMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
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tiw (7/16, 44%; p = 0.280) or 66 mcg tiw (2/18, 11%; p =
0.333; Figure 2) groups.
At Week 52, 0/18 patients in the IFN beta-1a 66 mcg tiw
group remained relapse-free, compared with 3/16
patients (19%) in the placebo group (p = 0.043; Figure 2).
The proportion of patients remaining relapse-free at Week
52 in the IFN beta-1a 44 mcg biw (1/17 patients, 6%; p =
0.330) and 44 mcg tiw (3/16 patients, 19%; p = 0.762)
groups did not differ significantly from the placebo group.
There were no significant differences between treatment
groups in any of the other secondary endpoints.
Analysis using imputed data showed that there were no
statistical differences between placebo and any of the IFN
beta-1a treatment groups in time to relapse. All treatment
groups showed a worsening of mean IBDQ and CDAI
scores from SD1 to Week 52. The placebo group had a
smaller mean increase in CDAI from SD1 to the end of
Week 26 (mean [SD] increase: 0.8 [25.3]) than the IFN
beta-1a treatment groups (mean [SD] increase for IFN
beta 1a, 44 mcg tiw: 9.7 [49.5]; 44 mcg biw: 11.6 [70.3];
66 mcg tiw: not reported).
The increase in mean ± SD erythrocyte sedimentation rate
from SD1 to end of treatment was smaller for the placebo
group (3.0 ± 12.2 mm/hr) than for any of the IFN beta-1a
treatment groups (range 15.3 ± 40.0 to 22.7 ± 22.3 mm/
hr). All treatment groups showed increases in C-reactive
protein level by the end of treatment, with the greatest
mean increase observed in the IFN beta-1a 44 mcg tiw
group. For patients with fistulas at the end of the study (2
patients in the placebo group, 3 in the IFN beta-1a 44 mcg
tiw group and 1 in the IFN beta-1a 66 mcg tiw group),
there were no changes from SD1 to end of treatment in
the number of fistulas.
At SD1, 1/17 patients (5.9%) in the IFN beta-1a 44 mcg
biw group and no patients in all other treatment groups
had a positive result for BAbs to IFN beta-1a. At Week 26,
4/16 patients (25.0%) in the IFN beta-1a 44 mcg tiw
group had positive BAb results, and at the end of treat-
ment positive BAbs results were found in 4/17 patients
(23.5%) in the IFN beta-1a 44 mcg biw group, 7/16
patients (43.8%) in the IFN beta-1a 44 mcg tiw group and
5/18 (27.8%) patients in the IFN beta-1a 66 mcg/tiw
group. No patients in the placebo group had a positive
result at Week 26 or at the end of treatment. Samples test-
ing positive for BAbs were also tested for NAbs. Of the
patients who were BAb-positive, 3 also tested positive for
NAbs; all 3 had received IFN beta-1a 44 mcg tiw.
Safety outcomes
A total of 452 AEs were reported in 62 (93%) of the 67
patients enrolled. The most common AEs were influenza-
like symptoms (24/67 patients; 36%), headache (22/67
patients; 33%) and injection-site reactions (18/67
patients; 27%) (Table 3). The majority of AEs were mild
or moderate in severity.
Eight severe AEs occurred in 4/16 patients (25.0%) in the
placebo group (headache, night sweats, nausea, tenesmus,
tooth disorder, increased creatine phosphokinase level,
involuntary muscle contractions, tremor). There were 4
severe AEs in 4/17 patients (23.5%) receiving IFN beta-1a
44 mcg biw (bronchitis, arthralgia, myalgia and pulmo-
Table 3: Summary of the most frequent adverse events that occurred during the study (frequency ≥ 10% of patients)
Number of patients (%)
Adverse event 
(preferred term)
Placebo (n = 16) IFN beta-1a 44 mcg 
biw (n = 17)
IFN beta-1a 44 mcg 
tiw (n = 16)
IFN beta-1a 66 mcg 
tiw (n = 18)
Total (n = 67)
Influenza-like symptoms 3 (18.8) 8 (47.1) 6 (37.5) 7 (38.9) 24 (35.8)
Headache 3 (18.8) 8 (47.1) 7 (43.8) 4 (22.2) 22 (32.8)
Injection-site reaction 2 (12.5) 5 (29.4) 6 (37.5) 5 (27.8) 18 (26.9)
Fever 2 (12.5) 3 (17.6) 5 (31.3) 6 (33.3) 16 (23.9)
Abdominal pain 4 (25.0) 2 (11.8) 5 (31.3) 5 (27.8) 16 (23.9)
Injection-site 
inflammation
2 (12.5) 3 (17.6) 5 (31.3) 5 (27.8) 15 (22.4)
Fatigue 3 (18.8) 3 (17.6) 4 (25.0) 2 (11.1) 12 (17.9)
Nausea 3 (18.8) 3 (17.6) 2 (12.5) 3 (16.7) 11 (16.4)
ESR increased 0 2 (11.8) 5 (31.3) 3 (16.7) 10 (14.9)
Arthralgia 2 (12.5) 4 (23.5) 3 (18.8) 1 (5.6) 10 (14.9)
Injection-site rash 0 3 (17.6) 3 (18.8) 2 (11.1) 8 (11.9)
Rhinitis 2 (12.5) 2 (11.8) 3 (18.8) 1 (5.6)_ 8 (11.9)
Myalgia 1 (6.3) 4 (23.5) 2 (12.5) 1 (5.6) 8 (11.9)
Injection-site pain 0 2 (11.8) 1 (6.3) 4 (22.2) 7 (10.4)
Anaemia 0 4 (23.5) 2 (12.5) 1 (5.6) 7 (10.4)
biw: twice weekly; ESR: erythrocyte sedimentation rate; IFN: interferon; tiw: three times weeklyBMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
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nary embolism), 4 severe AEs in 4/16 patients (25.0%)
receiving IFN beta-1a 44 mcg tiw (abdominal pain, tenes-
mus, myalgia, tachycardia) and 4 severe AEs in 3/18
patients (16.7%) receiving IFN beta-1a 66 mcg tiw (3
cases of abdominal pain and 1 case of dehydration). There
were no life-threatening AEs.
No deaths were reported during this study. There were 4
serious AEs in 4 patients (2 events in the placebo group, 1
in the IFN beta-1a 44 mcg biw group and 1 in the IFN
beta-1a 66 mcg tiw group). Two of the events – severe pul-
monary emboli in a patient treated with IFN beta-1a 44
mcg biw and moderate cellulitis of the ear (infection) in a
patient treated with IFN beta-1a 66 mcg tiw – were consid-
ered 'possibly' related to study treatment. The other 2
events – moderate dyspnoea on exertion and moderate
lower gastrointestinal bleed (both in patients in the pla-
cebo group) – were considered 'unlikely' to be related to
study treatment. Ten patients withdrew from the study
because of AEs: 1 in the placebo group, 4 in the IFN beta-
1a 44 mcg biw group, 1 in the IFN beta-1a 44 mcg tiw
group and 4 in the IFN beta-1a 66 mcg tiw group.
The incidence of AEs known or suspected to be associated
with IFN therapy, such as influenza-like symptoms, injec-
tion-site reactions, hepatic abnormalities (particularly ele-
vated transaminase levels), cytopenias and depression,
was higher in the IFN beta-1a treatment groups than the
placebo group, but was consistent with previous experi-
ence with IFN therapy. All these events were mild-to-mod-
erate in severity.
In general, changes from SD1 in haematology, blood
chemistry and urinalysis parameters were either expected
effects of IFN beta-1a treatment or within the normal
range, and thus were not considered clinically meaning-
ful. No clear treatment- or dose-related effects on thyroid
function were observed. There were no clinically signifi-
cant changes from SD1 in vital signs over the course of the
study. Steroid tapering was similar for the four treatment
groups.
Discussion
Following a 26-week interim analysis of data collected
from 67 patients, this study demonstrated that IFN beta-
1a does not have superior efficacy to placebo for main-
taining remission in patients with CD. The study was,
therefore, terminated prematurely. An amendment to the
protocol permitted interim analysis of the secondary end-
points to allow for early study discontinuation in the case
of lack of efficacy. There was little difference between
treatment groups in terms of secondary endpoints. IFN
beta-1a was generally well tolerated at all doses studied,
including the highest dosage of 66 mcg tiw, and the over-
all safety profile was consistent with previous experience
in patients with MS.
The most common AEs observed, such as influenza-like
symptoms, headache and injection-site reactions, were
more frequent in the IFN beta-1a treatment groups than in
the placebo group. However, these AEs are among the
most common side-effects seen with IFN beta-1a in
patients with MS [21], and therefore effective strategies are
already in place for their management. For example, influ-
enza-like symptoms can be treated using non-steroidal
anti-inflammatory drugs, such as ibuprofen, and novel
injection devices and formulations have been developed
to minimize injection-site reactions [22]. In this study,
IFN beta-1a was administered at a higher dose than that
used in MS. Importantly, the high dosage of 66 mcg tiw
was also generally well tolerated and was associated with
a similar incidence of AEs to the 44 mcg tiw dosage indi-
cated in MS.
Despite the similarities between the pathogenic mecha-
nisms of CD and MS, and the promising match between
the mechanism of action of IFN beta-1a and potential
therapeutic targets in CD, this study indicates that IFN
beta-1a is ineffective for the treatment of CD at the doses
evaluated. One explanation for the different effects in MS
and CD may be the many pathogenic pathways that IFN
beta is thought to influence in MS [17]. As well as down-
modulating T-cell activation and differentiation to Th1-
type CD4+ cells, IFN beta is also believed to inhibit acti-
vated Th1-cell trafficking across the blood-brain barrier
and to prevent T-cell reactivation in the central nervous
system [17]. If the efficacy of IFN beta in MS is due more
to its effects on these last two processes (specific to MS)
than on the induction of Th1-type CD4+ cells (important
in MS and CD), this could explain its lack of efficacy in
CD.
Although the percentage of patients relapse-free at Week
52 was significantly lower in the IFN beta-1a 66 mcg tiw
group than in the placebo group, this finding was not seen
with the other two IFN beta dosing regimens nor with the
primary or other secondary endpoints. Furthermore,
given the low patient numbers in this analysis, it is not
possible to conclude that IFN beta-1a may worsen CD.
Clinical experience with type I IFNs for the treatment of
CD is very limited. Few studies have been reported, all of
which included only a small number of patients and
results were variable [23-25]. Similarly, clinical studies of
IFN alpha or IFN beta in patients with ulcerative colitis
(UC) have reported promising results [26-28] or a lack of
efficacy [29,30]. Furthermore, isolated reports of UC in
patients receiving IFN beta-1a for MS [31] or IFN alpha for
hepatitis C infection [32,33] do not support a therapeuticBMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
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role for type I IFNs in the treatment of inflammatory
bowel disease.
Although the results reported here suggest that IFN beta-
1a is not an effective treatment for CD, these results
should be considered in the context of the low patient
numbers and high drop-out rate. Only 67 patients of a
planned recruitment target of 192 patients (35%) were
randomized to treatment. Of these patients only 20
(10.4% of the target number) completed the study; nota-
bly, treatment failures were the most common cause of
study drop-out. Thus, the findings reported here are based
on a very small number of patients, as with other studies
of IFNs in UC and CD.
Despite the lack of efficacy reported here, the results of
this study do lend further support to the favourable safety
profile of this treatment, which has already been demon-
strated in patients with MS. Moreover, these results indi-
cate that higher IFN beta-1a doses may offer a similar
safety profile to the dose currently indicated in patients
with MS.
Conclusion
Overall, analyses showed no difference in efficacy
between the IFN beta-1a treatment groups and placebo for
maintaining remission in patients with CD. However, IFN
beta-1a treatment was generally well tolerated, even at the
highest dosage of 66 mcg tiw, further supporting the
favourable safety profile of this treatment, both at the
dose indicated for MS and at higher doses.
Competing interests
CPR and HG are employees of Merck Serono S.A. –
Geneva. At the time of the study, SBH was a consultant for
Merck Serono S.A. – Geneva, who also provided his insti-
tution with clinical research funding for this trial. JOH, RT
and IS have no competing interests.
Authors' contributions
JOH, RT and IS were involved in the initial protocol
design, patient recruitment and assessment. CPR and HG
were involved in the evaluation of the data. All authors
were involved in the writing of the manuscript. All
authors have seen and approved the final manuscript.
Acknowledgements
We acknowledge the valuable contribution of the following study investiga-
tors:
USA: G Bonner, R Fogel, S Galandiuk, D Geenan, S Hauser, J Hanson, D 
Helper, R Holmes, J Jackson, M Kamionkowski, R Kania, M McKinley, P 
Moses, R Panaccione, W Priebe, D Riff, S Sacks, P Schleinitz, J Schwartz, J 
Schwartz, I Shafran, D Silvers, R Wohlman, E Eyring, B Kaufman, A Blumen-
feld; Germany: D Hüppe, S Schreiber, B Bokemeyer, K Jessen; UK: J 
Hunter, KD Bardhan, RJ Dickinson, JRB Green; Norway: E Aadland; Bel-
gium: P Rutgeerts; Sweden: O Suhr; Yugoslavia: T Milosavijevic, G Gol-
ubovic, S Lukacevic, R Tomasevic.
The authors thank Ruth Bentley and Andrea Plant of Caudex Medical (sup-
ported by Merck Serono S.A. – Geneva) for her assistance with the prepa-
ration of this manuscript.
References
1. Fiocchi C: Inflammatory bowel disease: etiology and patho-
genesis.  Gastroenterology 1998, 115(1):182-205.
2. Pavli P, Cavanaugh J, Grimm M: Inflammatory bowel disease:
germs or genes?  Lancet 1996, 347(9010):1198.
3. Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S: New insights
into inflammatory bowel disease pathophysiology: paving
the way for novel therapeutic targets.  Curr Drug Targets 2008,
9(5):413-418.
4. Hanauer SB: Inflammatory bowel disease: epidemiology,
pathogenesis, and therapeutic opportunities.  Inflamm Bowel
Dis 2006, 12(Suppl 1):S3-S9.
5. Neuman MG: Immune dysfunction in inflammatory bowel dis-
ease.  Transl Res 2007, 149(4):173-186.
6. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A,
Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand
H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek
G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert
F, Mitchell R, Hawkey CJ: European evidence based consensus
on the diagnosis and management of Crohn's disease: special
situations.  Gut 2006, 55(Suppl 1):i36-i58.
7. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes
K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche
C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W: European evi-
dence based consensus on the diagnosis and management of
Crohn's disease: definitions and diagnosis.  Gut 2006, 55(Suppl
1):i1-i15.
8. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A,
D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF,
Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen
NJ: European evidence based consensus on the diagnosis and
management of Crohn's disease: current management.  Gut
2006, 55(Suppl 1):i16-i35.
9. Buning C, Lochs H: Conventional therapy for Crohn's disease.
World J Gastroenterol 2006, 12(30):4794-4806.
10. D'Haens G, Daperno M: Advances in biologic therapy for ulcer-
ative colitis and Crohn's disease.  Curr Gastroenterol Rep 2006,
8(6):506-512.
11. Peluso I, Pallone F, Monteleone G: Interleukin-12 and Th1
immune response in Crohn's disease: pathogenetic rele-
vance and therapeutic implication.  World J Gastroenterol 2006,
12(35):5606-5610.
12. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza
F, Pallone F: Interleukin 12 is expressed and actively released
by Crohn's disease intestinal lamina propria mononuclear
cells.  Gastroenterology 1997, 112(4):1169-1178.
13. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A,
Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S: Type 1 T-
helper cell predominance and interleukin-12 expression in
the gut of patients with Crohn's disease.  Am J Pathol 1997,
150(3):823-832.
14. Berrebi D, Besnard M, Fromont-Hankard G, Paris R, Mougenot JF, De
Lagausie P, Emilie D, Cezard JP, Navarro J, Peuchmaur M: Inter-
leukin-12 expression is focally enhanced in the gastric
mucosa of pediatric patients with Crohn's disease.  Am J Pathol
1998, 152(3):667-672.
15. Monteleone G, MacDonald TT, Wathen NC, Pallone WF, Pender SLF:
Enhancing lamina propria Th1 cell responses with IL-12 pro-
duces severe tissue injury.  Gasteroenterology 1999,
117:1069-1077.
16. Neurath MF, Fuss I, Kelsall B, Meyer zum Buschenfelde KH, Strober
W:  Effect of IL-12 and antibodies to IL-12 on established
granulomatous colitis in mice.  Ann N Y Acad Sci 1996,
795:368-370.
17. Chofflon M: Mechanisms of action for treatments in multiple
sclerosis: Does a heterogeneous disease demand a multi-tar-
geted therapeutic approach?  BioDrugs 2005, 19(5):299-308.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2009, 9:22 http://www.biomedcentral.com/1471-230X/9/22
Page 10 of 10
(page number not for citation purposes)
18. Randomised double-blind placebo-controlled study of inter-
feron beta-1a in relapsing/remitting multiple sclerosis.
PRISMS (Prevention of Relapses and Disability by Interferon
beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet 1998, 352(9139):1498-1504.
19. Guidance for industry. E6 Good Clinical Practice: consoli-
dated guidance   [http://www.fda.gov/cder/guidance/959fnl.pdf]
20. Declaration of Helsinki: Ethical principles for medical
research involving human subjects   [http://www.wma.net/e/pol
icy/b3.htm]
21. Rebif® Prescribing Information   [http://www.fda.gov/cder/foi/
label/2002/ifnbser030702LB.pdf]
22. Ross AP, Wynn DR: Management of Treatment Side Effects.
International Journal of MS Care 2006, Feb(Suppl):26-31.
23. Vantrappen G, Coremans G, Billiau A, De Somer P: Treatment of
Crohn's disease with interferon. A preliminary clinical trial.
Acta Clin Belg 1980, 35(4):238-242.
24. Wirth HP, Zala G, Meyenberger C, Jost R, Ammann R, Munch R:
[Alpha-interferon therapy in Crohn's disease: initial clinical
results].  Schweiz Med Wochenschr 1993, 123(27–28):1384-1388.
25. Gasche C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M,
Wirth HP, Gangl A, Lochs H: Prospective evaluation of inter-
feron-alpha in treatment of chronic active Crohn's disease.
Dig Dis Sci 1995, 40(4):800-804.
26. Musch E, Andus T, Malek M, Chrissafidou A, Schulz M: Successful
treatment of steroid refractory active ulcerative colitis with
natural interferon-beta – an open long-term trial.  Z Gastroen-
terol 2007, 45(12):1235-1240.
27. Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, Theuer
D, Mohrle J, Schreiber S: Interferon beta-1a in ulcerative colitis:
a placebo controlled, randomised, dose escalating study.  Gut
2003, 52(9):1286-1290.
28. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis
P, Munkholm P: An open-labeled, randomized study compar-
ing systemic interferon-alpha-2A and prednisolone enemas
in the treatment of left-sided ulcerative colitis.  Am J Gastroen-
terol 2001, 96(6):1807-1815.
29. Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S,
Krakamp B, Malek M, Malchow H, Zavada F, Engelberg Feurle G:
Interferon-beta-1a for the treatment of steroid-refractory
ulcerative colitis: a randomized, double-blind, placebo-con-
trolled trial.  Clin Gastroenterol Hepatol 2005, 3(6):581-586.
30. Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J,
Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H:
Clinical trial: a multicentre, randomized, double-blind, pla-
cebo-controlled, dose-finding, phase II study of subcutaneous
interferon-beta-1a in moderately active ulcerative colitis.  Ali-
ment Pharmacol Ther 2008, 28(6):758-767.
31. Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B,
Baumgart DC: Development of ulcerative colitis in a patient
with multiple sclerosis following treatment with interferon
beta 1a.  World J Gastroenterol 2007, 13(26):3638-3640.
32. Mitoro A, Yoshikawa M, Yamamoto K, Mimura M, Yoshikawa Y, Shi-
roi A, Mochi T, Sakamoto T, Yamao J, Kikuchi E, Fukui H, Tsujii T:
Exacerbation of ulcerative colitis during alpha-interferon
therapy for chronic hepatitis C.  Intern Med 1993, 32(4):327-331.
33. Watanabe T, Inoue M, Harada K, Homma N, Uchida M, Ogata N, Fun-
ada R, Hasegawa K, Soga K, Shibasaki K: A case of exacerbation of
ulcerative colitis induced by combination therapy with PEG-
interferon alpha-2b and ribavirin.  Gut 2006, 55(11):1682-1683.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/9/22/pre
pub